Materiality pending
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
- Myriad Genetics reported Q1 revenue of $202.2 million, up 11.6% YoY. - EPS improved to -$0.01 from -$0.21 YoY, with a positive surprise. - Revenue breakdown shows mixed results across different product segments. - MYGN stock returned -1.8% in the past month, Zacks Rank #4 (Sell). Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Earnings
- Myriad Genetics reported Q1 revenue of $202.2 million, up 11.6% YoY.
- EPS improved to -$0.01 from -$0.21 YoY, with a positive surprise.
- Revenue breakdown shows mixed results across different product segments.
- MYGN stock returned -1.8% in the past month, Zacks Rank #4 (Sell).
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.